This analysis reveals improved clinical efficacy and reduced symptoms in patients with postherpetic neuralgia using neuromodulation and opioid-sparing analgesics.
Postherpetic neuralgia (PHN) is a common complication of herpes zoster, which seriously affects patients' quality of life. This study analysed the synergistic effect of neuromodulation and opioid dilution analgesics in the treatment of PHN. 120 patients with PHN from Affiliated Hospital of Southwest Medical University between December 2020 and December 2023 were categorized into PR and PO groups, both groups were treated with pulsed radiofrequency, PO group was added with Oxycodone hydrochloride. VAS scores, inflammatory factor indexes [tumour necrosis factor-? (TNF-?), interleukin-1? (IL-1?), interleukin-2 (IL-2), interleukin-10 (IL-10)], immune indexes [percentage of CD4+ T cells, CD8+ T cells, CD4+ /CD8+] and clinical efficacy were mainly evaluated. Secondary indicators included sleep quality (PSQI) scores, anxiety self-assessment (SAS) scores, disease control time, adverse reactions and recurrence rates. Post-treatment, both groups’ indicators were significantly improved. IL-2 and IL-10 levels, CD4+ T cells percentage, CD4+ /CD8+ and clinical efficacy were higher in PO group than PR group. VAS score, TNF-? and IL-1? levels, CD8+ T cells percentage, PSQI score, SAS score, disease control time, adverse reaction and recurrence rate were lower than PR group (P<0.05). The combination treatment efficacy of PHN is remarkable and is worth promoting its use in the clinic.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: